Gilead Says Drug Patent Is Invalid, So No Infringement
Gilead Sciences has defended litigation it filed seeking to revoke a biotech company's patent for a hepatitis C treatment, saying the claimed scientific creation is not sufficiently innovative after earlier medical...To view the full article, register now.
Already a subscriber? Click here to view full article